Co-Authors
This is a "connection" page, showing publications co-authored by Benjamin Mcdonald and David Rubin.
Connection Strength
3.092
-
Clinical Trials for Perianal Crohn's Disease: A Call for a Revised Approach. Gastroenterology. 2025 Aug; 169(2):183-187.e1.
Score: 0.898
-
IL-23 Monoclonal Antibodies for IBD: So Many, So Different? J Crohns Colitis. 2022 May 11; 16(Supplement_2):ii42-ii53.
Score: 0.737
-
Impact of Upadacitinib on Cardiovascular Events and Lipid Values in Older Inflammatory Bowel Disease Patients With Baseline Cardiovascular Risk. Am J Gastroenterol. 2026 Jun 09.
Score: 0.244
-
Dual-targeted therapy with risankizumab and upadacitinib in medically complex Crohn's disease. Crohns Colitis 360. 2026 Apr; 8(2):otag049.
Score: 0.244
-
Erratum to: New Eczematous Eruption in Patients With Inflammatory Bowel Disease Who Stop Janus Kinase Inhibitors. Am J Gastroenterol. 2026 Feb 05.
Score: 0.239
-
New Eczematous Eruption in Patients With Inflammatory Bowel Disease Who Stop Janus Kinase Inhibitors. Am J Gastroenterol. 2026 01 01; 121(1):268-273.
Score: 0.231
-
Comparison Between Adalimumab and Infliximab in Perianal Crohn's Disease: A Systematic Review and Meta-Analysis. Gastro Hep Adv. 2025; 4(8):100697.
Score: 0.227
-
Immediate Infusion Reaction to Intravenous Risankizumab-rzaa but Subsequent Tolerance to Subcutaneous Risankizumab-rzaa. ACG Case Rep J. 2024 Nov; 11(11):e01546.
Score: 0.219
-
Perianal Fistulizing Crohn's Disease-Associated Anorectal and Fistula Cancers: Systematic Review and Expert Consensus. Clin Gastroenterol Hepatol. 2025 May; 23(6):927-945.e2.
Score: 0.053